| 1 |
34741486 | Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease. | 2022 Feb |
2 |
| 2 |
35065083 | The neuroinflammatory role of glucocerebrosidase in Parkinson's disease. | 2022 Apr 1 |
2 |
| 3 |
35636011 | Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography/tandem mass spectrometry. | 2022 Aug 5 |
1 |
| 4 |
34151863 | Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations. | 2021 |
1 |
| 5 |
34485083 | Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease. | 2021 Dec |
2 |
| 6 |
32044242 | Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. | 2020 Apr |
1 |
| 7 |
29385658 | The role of glucocerebrosidase in Parkinson disease pathogenesis. | 2018 Oct |
1 |
| 8 |
28166796 | Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease. | 2017 Feb 6 |
1 |
| 9 |
28812093 | A convenient approach to facilitate monitoring Gaucher disease progression and therapeutic response. | 2017 Sep 8 |
2 |
| 10 |
28847804 | Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease. | 2017 Oct 4 |
3 |
| 11 |
26387627 | Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. | 2016 Feb |
1 |